Eli Lilly’s Stock Performance and Recent Developments

Shares of Eli Lilly, known for its weight-loss medications Mounjaro and Zepbound, saw a modest increase of 3.6% by 10:30 a.m. ET. This uptick came amidst favorable news for Lilly and some setbacks for its competitor, Novo Nordisk.

In the morning, Novo Nordisk, the Danish pharmaceutical firm behind the GLP-1 drugs Wegovy and Ozempic, shared findings from clinical trials of its new drug CagriSema. This medication combines the amylin analog cagrylintide with Novo’s semaglutide. After 84 weeks of treatment, patients using CagriSema lost around 23% of their body weight, while those on Eli Lilly’s tirzepatide lost 25.5%. Essentially, Novo’s new drug performed better than Lilly’s, putting Lilly in a slightly challenging position.

But that’s not all. Eli Lilly also introduced the KwikPen for Zepbound, a system that essentially functions like a large syringe. While it might not be a revolutionary advancement, it allows Zepbound users to purchase a month’s worth of medication in one pen, which can be divided into four doses. This could make weekly administration a bit simpler.

Interestingly, the price for Zepbound will remain at $299 per month for the lowest dose. Using the KwikPen instead of multiple devices should help patients manage their medication more easily. There might even be some cost savings in producing fewer syringes, but overall, the financial benefits for patients are likely to be minimal.

Last quarter, Zepbound brought in $4.2 billion in revenue for Lilly. Yet, what seems to be more significant for Lilly right now is that Novo appeared to stumble with CagriSema.

Before considering an investment in Eli Lilly, it may be worth noting that a research team has highlighted several stocks they believe could yield strong returns in the coming years. Eli Lilly isn’t featured, so potential investors might want to weigh their options carefully.